Virupaksha
Virupaksha Organics Limited is a Hyderabad-headquartered pharmaceutical manufacturer founded in 2003, producing active pharmaceutical ingredients and intermediates across 10+ therapeutic categories for global generic and innovator pharma companies in 100+ countries, with 7 manufacturing units.
- Company typePrivate
- Founded2003
- HeadquartersHyderabad, India
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Virupaksha does
Virupaksha Organics Limited is a Hyderabad-based pharmaceutical manufacturer founded in 2003 by Chandra Mouliswar Reddy Gangavaram, specializing in active pharmaceutical ingredients (APIs) and advanced intermediates across more than 10 therapeutic segments including anti-histamine, anti-fungal, analgesic, anti-depressant, anti-diabetic, anti-asthmatic, anti-hypertensive, anti-ulcerative, and anti-epileptic categories. The company operates 7 manufacturing units with over 1,000 kL of aggregate reactor capacity spread across Hyderabad (Units 1, 2, 4, 5, 6) and Karnataka/Humnabad (Unit 3), plus the 280 kL Oxygenta Pharma facility acquired in 2024 in Sadasivapet, and a dedicated R&D Centre focused on novel clinical API discovery and contract research. The technology base is built around flow chemistry capabilities, fully backward-integrated intermediate production, and proprietary non-infringing process routes that enable first-to-file generic opportunities, supported by regulatory compliance with USFDA, EDQM, PMDA, TGA, ANVISA, MFDS, COFEPRIS, and WHO GMP.
Virupaksha firmographics
Firmographics- Name
- Virupaksha
- Legal name
- Virupaksha Organics Limited
- Website
- https://virupaksha.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Virupaksha Organics Limited is a Hyderabad-headquartered pharmaceutical manufacturer founded in 2003, producing active pharmaceutical ingredients and intermediates across 10+ therapeutic categories for global generic and innovator pharma companies in 100+ countries, with 7 manufacturing units.
- Ownership category
- akta.pro rank
Virupaksha industry classification
Industry- Product category
- Active Pharmaceutical Ingredients (APIs) Manufacturing
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Small-Molecule API & Intermediates CDMO (HLAGABAA)
- akta.pro secondary industries
- Flow Chemistry & Process Intensification Services (HLAGAHAK), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)
Keywords
Where Virupaksha is headquartered
LocationHeadquarters
- HQ city
- Hyderabad
- HQ country
- India
- HQ region
- Asia
Offices8 records
Markets served
Virupaksha business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Active Pharmaceutical Ingredients (APIs) Sales: Manufacturing and sale of high-quality APIs across more than 10 therapeutic segments including anti-histamine, anti-fungal, analgesic, anti-depressant, anti-diabetic, anti-asthmatic, anti-anginal, anti-hypertensive, anti-ulcerative, and anti-epileptic categories. Revenue reported at Rs 811 crore for FY 2024-25.
- Pharmaceutical Intermediates Sales: Production and sale of high-quality intermediates across therapeutic areas including anti-diabetic, anti-depressant/anti-psychotic, anti-fungal, anti-histamine, and others, supported by robust backward integration.
- CDMO Services: Contract Development and Manufacturing Organization services partnering with innovator and generic API companies offering non-infringing process support for first to file. Includes expertise in process development, optimization, analytical method validation, and complex molecule synthesis.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Virupaksha product offering
Product offeringCore offering
Virupaksha manufactures and supplies Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates for global pharmaceutical brands across more than 10 therapeutic segments. The company offers Contract Development and Manufacturing Organization (CDMO) services for non-infringing process support to innovator and generic API companies, and maintains dedicated flow chemistry capabilities for safer and sustainable conventional processes. Operations are supported by 7 manufacturing units in Hyderabad and Karnataka with a collective team of over 1,800 people.
Product overview
Virupaksha Organics is a pharmaceutical manufacturing company that operates as a single unified product offering centered around Active Pharmaceutical Ingredients (APIs) and Intermediates production. The company produces high quality APIs across 10+ therapeutic segments (anti-histamine, anti-fungal, analgesic, anti-depressant, anti-asthmatic, anti-diabetic, etc.) and offers pharmaceutical intermediates with backward integration. The portfolio includes CDMO (Contract Development and Manufacturing Organization) services for process support to innovators and generics, Formulations Division for complex generic products, and Flow Chemistry Services for sustainable manufacturing. An acquired brand, Oxygenta Pharma (2024), expands their APIs and Advanced Intermediates capacity.
Differentiator
Problem solved
Functional benefit
Brands
- Virupaksha Formulations Division: Development of complex and generic products for domestic and regulatory markets
- Virupaksha R&D Centre
- Oxygenta Pharma
Products and services
- Active Pharmaceutical Ingredients (APIs) High quality Active Pharmaceutical Ingredients manufactured across more than 10 therapeutic segments including anti-histamine, anti-fungal, analgesic, anti-depressant, anti-asthmatic, anti-diabetic, anti-hypercholesteromia, anti-hypertensive, anti-ulcerative, and anti-epileptic categories, with DMF/CEP certifications. Targeted at global generic and innovator pharmaceutical manufacturers.
- Pharmaceutical Intermediates High quality pharmaceutical intermediates manufactured with robust backward integration, spanning therapeutic areas including anti-diabetic, anti-depressant/anti-psychotic, anti-fungal, anti-histamine, anti-hypercholesteromia, analgesic, neuropathic heredofamilial amyloidosis, anti-neoplastic agents, non-ergot dopamine agonists, and anti-epileptic applications. Supplied to API manufacturers and pharmaceutical companies globally.
- CDMO Services Contract Development and Manufacturing Organization services partnering with innovator and generic API companies, offering non-infringing process support for first-to-file, process development, optimization, analytical method validation, and complex molecule synthesis. Targeted at innovator and generic pharmaceutical companies needing custom manufacturing.
- Flow Chemistry Services Niche flow chemistry capabilities using advanced technology to make conventional processes safer and sustainable, with a dedicated team trained at premier research institutes. Serves pharmaceutical companies requiring safe, scalable, and sustainable process chemistry solutions.
Quantifiable outcome
- Revenue of Rs 811 crore with profit of Rs 78 crore in FY 2024-25
Companies that use Virupaksha
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Virupaksha technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Virupaksha partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- KFin Technologies LimitedoperationalRegistrar and Transfer Agent for Virupaksha Organics' IPO and shareholder services. Located at Selenium, Tower B, Plot No. 31 and 32, Gachibowli, Financial District, Hyderabad. Handles investor grievances and equity share registry services.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
Virupaksha competitors and assessment
Company assessmentDirect peers
- Shilpa Medicare: Indian API and intermediates manufacturer with regulated-market approvals and oncology focus; comparable to Virupaksha's therapeutic breadth and CDMO offerings.
- Granules India: Vertically integrated Indian manufacturer of APIs, intermediates, and finished dosages, comparable to Virupaksha in therapeutic breadth and export-driven generic business.
- Divi's Laboratories: India-based API and intermediates manufacturer with strong backward integration and CDMO services; directly comparable to Virupaksha in small-molecule APIs, custom synthesis, and innovator partnerships.
- Laurus Labs: Indian API and CDMO company with comparable therapeutic breadth, regulated-market approvals (USFDA, EDQM), and a similar mix of generics and innovator contract manufacturing.
- Suven Pharmaceuticals: Indian CDMO/API company with strong innovator and NCE process chemistry focus, overlapping with Virupaksha's flow chemistry and CRAMS capabilities.
- Neuland Laboratories: India-based API manufacturer and CDMO with USFDA-inspected facilities, focused on small-molecule APIs and intermediates — a close mid-cap comparable to Virupaksha's profile.
Broad incumbents
- Aurobindo Pharma: Large Indian generic pharmaceutical and API manufacturer; competes with Virupaksha in several API therapeutic segments and has a much broader finished-dose footprint.
- Dr. Reddy's Laboratories: Major Indian pharmaceutical company with significant API and CDMO operations; a much larger incumbent that overlaps with Virupaksha in API manufacturing and regulated-market supply.
- Piramal Pharma: Diversified Indian pharma and CDMO player with global manufacturing and contract development services, competing for similar innovator and generic API contracts.
Emerging players
- Sequent Scientific: Indian manufacturer with API and CDMO operations across human and animal health; smaller scale than Virupaksha but competes in similar regulated API markets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Virupaksha social profiles
Digital presenceVirupaksha compliance and trust
Trust signalCompliance30 records
Virupaksha financial estimates
Financial estimateRevenue estimate
Valuation estimate
Virupaksha leadership team
Management profileNumber of profiles
Profiles11 records
Virupaksha subsidiaries and ownership
Company hierarchySubsidiaries3 records
Virupaksha funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Virupaksha M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Virupaksha
What does Virupaksha do?
Virupaksha manufactures and supplies Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates for global pharmaceutical brands across more than 10 therapeutic segments. The company offers Contract Development and Manufacturing Organization (CDMO) services for non-infringing process support to innovator and generic API companies, and maintains dedicated flow chemistry capabilities for safer and sustainable conventional processes. Operations are supported by 7 manufacturing units in Hyderabad and Karnataka with a collective team of over 1,800 people.
Is Virupaksha a public or private company?
Virupaksha is a private company. It is classified as family owned and is currently operating.
When was Virupaksha founded?
Virupaksha was founded in 2003. It employs 11 to 50 people.
Where is Virupaksha based?
Virupaksha is headquartered in Hyderabad, India, in the Asia region.
How does Virupaksha make money?
Three revenue lines are on record. Active Pharmaceutical Ingredients (APIs) Sales are the primary driver. The others are pharmaceutical Intermediates Sales and CDMO Services.
Who are Virupaksha's main competitors?
Direct peers on record are Shilpa Medicare, Granules India, Divi's Laboratories, Laurus Labs, Suven Pharmaceuticals and Neuland Laboratories. Broad incumbents are Aurobindo Pharma, Dr. Reddy's Laboratories and Piramal Pharma. Sequent Scientific is listed as an emerging player.
Does Virupaksha have an API?
No public API is recorded for Virupaksha.
What industry is Virupaksha in?
Virupaksha's product category is Active Pharmaceutical Ingredients (APIs) Manufacturing. Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGAHAK, Flow Chemistry & Process Intensification Services. Its NAICS code is 3254 and its SIC code is 2834.